ArticleEMBO molecular medicine2012
Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers.
Article in EMBO molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Polymer Drug Conjugate: A Revolution in Drug Delivery.AAPS PharmSciTech · 2026Review
- Unlocking Transplant Tolerance with Biomaterials.Advanced healthcare materials · 2025Review
- Oral Vaccines: A Better Future of Immunization.Vaccines · 2023Review
- Nanomaterials and Their Impact on the Immune System.International journal of molecular sciences · 2023Review
- Intestinal Anastomotic Healing: What do We Know About Processes Behind Anastomotic Complications.Frontiers in surgery · 2022Review
- Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases.Molecules (Basel, Switzerland) · 2021Review
- Reactive Oxygen Species Interact With NLRP3 Inflammasomes and Are Involved in the Inflammation of Sepsis: From Mechanism to Treatment of Progression.Frontiers in physiology · 2020Review
- The ABP Dendrimer, a Drug-Candidate against Inflammatory Diseases That Triggers the Activation of Interleukin-10 Producing Immune Cells.Molecules (Basel, Switzerland) · 2018Review
- Pro-Inflammatory Versus Anti-Inflammatory Effects of Dendrimers: The Two Faces of Immuno-Modulatory Nanoparticles.Nanomaterials (Basel, Switzerland) · 2017Review
- Nanoparticles and direct immunosuppression.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Controlling the cytokine storm in severe bacterial diarrhoea with an oral Toll-like receptor 4 antagonist.Immunology · 2016Article
- Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis.Nanomedicine : nanotechnology, biology, and medicine · 2015Article
- Molecular Modeling to Study Dendrimers for Biomedical Applications.Molecules (Basel, Switzerland) · 2014Review
- Applications of nanotechnology for immunology.Nature reviews. Immunology · 2013Review
- Dendrimers branch out to support mucosal integrity.EMBO molecular medicine · 2012Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
Intestinal pathogens use the host's excessive inflammatory cytokine response, designed to eliminate dangerous bacteria, to disrupt epithelial gut wall integrity and promote their tissue invasion. We sought to develop a non-antibiotic-based approach to prevent this injury. Molecular docking studies suggested that glycosylated dendrimers block the TLR4-MD-2-LPS complex, and a 13.6 kDa polyamidoamine (PAMAM) dendrimer glucosamine (DG) reduced the induction of human monocyte interleukin (IL)-6 by Gram-negative bacteria. In a rabbit model of shigellosis, PAMAM-DG prevented epithelial gut wall damage and intestinal villous destruction, reduced local IL-6 and IL-8 expression, and minimized bacterial invasion. Computational modelling studies identified a 3.3 kDa polypropyletherimine (PETIM)-DG as the smallest likely bioactive molecule. In human monocytes, high purity PETIM-DG potently inhibited Shigella Lipid A-induced IL-6 expression. In rabbits, PETIM-DG prevented Shigella-induced epithelial gut wall damage, reduced local IL-6 and IL-8 expression, and minimized bacterial invasion. There was no change in β-defensin, IL-10, interferon-β, transforming growth factor-β, CD3 or FoxP3 expression. Small and orally delivered DG could be useful for preventing gut wall tissue damage in a wide spectrum of infectious diarrhoeal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.